Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin/Paclitaxel/CT-322 vs Carboplatin/Paclitaxel/Bevacizumab in First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (Non-Squamous)
2008-007768-41Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing CT-322 + carboplatin + paclitaxel with Bevacizumab + carboplatin + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Jul 2009; status: completed.
02
Drugs
pegdinetanibbevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2008-007768-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007768-41.